PTPI vs PFE

For growth investors, Pfizer Inc.

(PFE) is the stronger pick with -1. 6% revenue growth year-over-year, versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). Pfizer Inc. (PFE) offers the better valuation at 18. 9x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Pfizer Inc. (PFE) a "Hold" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Pfizer Inc.

(PFE) delivered a total return of -14. 8%, compared to -100. 0% for Petros Pharmaceuticals, Inc. (PTPI). Over 10 years, the gap is even starker: PFE returned +28. 5% versus PTPI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 49β versus Petros Pharmaceuticals, Inc. 's 1. 45β — meaning PTPI is approximately 195% more volatile than PFE relative to the S&P 500.

By revenue growth (latest reported year), Pfizer Inc.

(PFE) is pulling ahead at -1. 6% versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). On earnings-per-share growth, the picture is similar: Petros Pharmaceuticals, Inc. grew EPS 47. 4% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, PTPI leads at -13. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pfizer Inc.

(PFE) is the more profitable company, earning 12. 4% net margin versus -280. 1% for Petros Pharmaceuticals, Inc. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus -345. 8% for PTPI. At the gross margin level — before operating expenses — PTPI leads at 76. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

All stocks in this comparison pay dividends.

Petros Pharmaceuticals, Inc. (PTPI) offers the highest yield at 100. 0%, versus 6. 7% for Pfizer Inc. (PFE).

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 49), 6. 7% yield). Both have compounded well over 10 years (PFE: +28. 5%, PTPI: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.